宏源药业
(301246)
| 流通市值：26.49亿 | | | 总市值：65.84亿 |
| 流通股本：1.61亿 | | | 总股本：4.00亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,322,234,413.75 | 898,125,095.81 | 426,063,885 | 2,054,881,990.91 |
| 营业收入 | 1,322,234,413.75 | 898,125,095.81 | 426,063,885 | 2,054,881,990.91 |
| 二、营业总成本 | 1,265,739,711.39 | 849,871,656.81 | 393,251,587.27 | 1,965,280,503.57 |
| 营业成本 | 1,156,434,332.78 | 772,818,932.43 | 359,024,437.28 | 1,788,014,080.66 |
| 税金及附加 | 7,021,259.82 | 4,738,652.29 | 2,347,202.48 | 13,347,161.83 |
| 销售费用 | 26,484,405.67 | 18,176,756.12 | 8,475,283.66 | 37,690,489.34 |
| 管理费用 | 34,686,204.44 | 25,689,602.64 | 9,886,104.43 | 60,806,330.36 |
| 研发费用 | 41,660,613.38 | 30,793,313.49 | 15,176,270.87 | 68,816,103.15 |
| 财务费用 | -547,104.7 | -2,345,600.16 | -1,657,711.45 | -3,393,661.77 |
| 其中:利息费用 | 8,920,697.27 | 5,897,277.75 | 2,557,508 | 13,397,012.49 |
| 其中:利息收入 | 8,244,347.52 | 5,669,319.59 | 2,584,762.4 | 17,051,206.89 |
| 加:公允价值变动收益 | 734,829.45 | -460,372.1 | 3,996,997.27 | 2,860,235.62 |
| 加:投资收益 | 1,259,863.6 | 3,012,409.92 | -849,561.02 | 19,419,742.61 |
| 资产处置收益 | 94,503.36 | 75,199.82 | 75,199.82 | 568,537.69 |
| 资产减值损失(新) | -23,384,990.53 | -14,196,915.21 | -4,715,838.5 | -26,379,959.24 |
| 信用减值损失(新) | -1,547,449.72 | -2,121,421.93 | -135,590.14 | -4,511,454.35 |
| 其他收益 | 12,027,805.99 | 7,197,894.89 | 3,982,300.65 | 24,085,914.93 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 45,679,264.51 | 41,760,234.39 | 35,165,805.81 | 105,644,504.6 |
| 加:营业外收入 | 88,115.74 | 59,638.34 | 54,045.78 | 156,173.91 |
| 减:营业外支出 | 400,519.5 | 400,510.99 | 141,200.01 | 7,242,614.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 45,366,860.75 | 41,419,361.74 | 35,078,651.58 | 98,558,063.56 |
| 减:所得税费用 | 9,224,615.44 | 5,609,751.05 | 3,879,589.96 | 11,389,437.32 |
| 六、净利润 | 36,142,245.31 | 35,809,610.69 | 31,199,061.62 | 87,168,626.24 |
| 持续经营净利润 | 36,142,245.31 | 35,809,610.69 | 31,199,061.62 | 87,168,626.24 |
| 归属于母公司股东的净利润 | 36,142,245.31 | 35,809,610.69 | 31,199,061.62 | 87,168,626.24 |
| (一)基本每股收益 | 0.09 | 0.09 | 0.08 | 0.22 |
| (二)稀释每股收益 | 0.09 | 0.09 | 0.08 | 0.22 |
| 九、综合收益总额 | 36,142,245.31 | 35,809,610.69 | 31,199,061.62 | 87,168,626.24 |
| 归属于母公司股东的综合收益总额 | 36,142,245.31 | 35,809,610.69 | 31,199,061.62 | 87,168,626.24 |
| 公告日期 | 2024-10-25 | 2024-08-30 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |